Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer

Cancer Gene Therapy

Volumn 19, Issue 3, 2012, Pages 192-201

  Sathaiah, M ^a   Thirunavukkarasu, P ^a   O'Malley, M E ^a   Kavanagh, M A ^b   Ravindranathan, R ^a   Austin, F ^a   Guo, Z S ^a   Bartlett, D L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

apoptosis; Fas ligand; Fas receptor; oncolytic virus; vaccinia virus

Indexed keywords

FAS ANTIGEN; FAS LIGAND; ONCOLYTIC VIRUS; PROTEIN FAS RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOGENICITY; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; TUMOR REGRESSION; VIRUS REPLICATION;

MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 84857120837     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.77     Document Type: Article

References (48)

1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-659. (Pubitemid 46431984)
2. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231.
3. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev 2010; 21: 85-89.
4. Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004; 4: 901-917. (Pubitemid 38843227)
5. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66-73. (Pubitemid 30080989)
6. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumorselective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757. (Pubitemid 34013887)
7. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005; 65: 9991-9998. (Pubitemid 41541480)
8. Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008; 68: 2071-2075. (Pubitemid 351521777)
9. Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, Szalay AA. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14. 5L inactivation. Mol Genet Genomics 2009; 282: 417-435.
10. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-1642.
11. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 2008; 15: 115-125.
12. Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 2010; 120: 1551-1560.
13. Ziauddin MF, Guo ZS, O'Malley ME, Austin F, Popovic PJ, Kavanagh MA et al. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther 2010; 17: 550-559.
14. Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W et al. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006; 12: 5224-5230. (Pubitemid 44453352)
15. Alvarez-Breckenridge C, Kaur B, Chiocca EA. Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev 2009; 109: 3125-3140.
16. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 18: 1430-1439.
17. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-263.
18. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501. (Pubitemid 32201945)
19. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675. (Pubitemid 28267863)
20. Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999; 84: 239-243. (Pubitemid 29256748)
21. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000; 89: 127-132. (Pubitemid 30185920)
22. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007; 26: 3745-3757. (Pubitemid 46842709)
23. Guillen-Ahlers H, Suckow MA, Castellino FJ, Ploplis VA. Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS One 2010; 5: e9070.
24. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191: 1209-1220.
25. Taylor JM, Barry M. Near death experiences: poxvirus regulation of apoptotic death. Virology 2006; 344: 139-150. (Pubitemid 41814458)
26. McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7: 1217-1223. (Pubitemid 30488768)
27. Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol 1993; 74: 2347-2355. (Pubitemid 23332295)
28. Ennaciri J, Menezes J, Proulx F, Toledano BJ. Induction of apoptosis by herpes simplex virus-1 in neonatal, but not adult, neutrophils. Pediatr Res 2006; 59: 7-12.
29. O'Donnell DR, Milligan L, Stark JM. Induction of CD95 (Fas) and apoptosis in respiratory epithelial cell cultures following respiratory syncytial virus infection. Virology 1999; 257: 198-207. (Pubitemid 29391813)
30. Clarke P, Beckham JD, Leser JS, Hoyt CC, Tyler KL. Fasmediated apoptotic signaling in the mouse brain following reovirus infection. J Virol 2009; 83: 6161-6170.
31. Xu XN, Screaton GR, Gotch FM, Dong T, Tan R, Almond N et al. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997; 186: 7-16. (Pubitemid 27304842)
32. Chen X, Zachar V, ZdravkovicM, Guo M, Ebbesen P, Liu X. Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotropic virus type I Tax transactivator. J Gen Virol 1997; 78(Pt 12): 3277-3285. (Pubitemid 27511318)
33. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996; 70: 199-206. (Pubitemid 126508786)
34. Liao H, Xu J, Huang J. FasL/Fas pathway is involved in dengue virus induced apoptosis of the vascular endothelial cells. J Med Virol 2010; 82: 1392-1399.
35. Krzyzowska M, Cymerys J, Winnicka A, Niemialtowski M. Involvement of Fas and FasL in Ectromelia virus-induced apoptosis in mouse brain. Virus Res 2006; 115: 141-149. (Pubitemid 43088641)
36. Gaddy DF, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 2007; 81: 2792-2804. (Pubitemid 46447043)
37. Shunmei E, Zhao Y, Huang Y, Lai K, Chen C, Zeng J et al. Heat shock factor 1 is a transcription factor of Fas gene. Mol Cells 2010; 29: 527-531.
38. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C et al. Poxviruses and immune evasion. Annu Rev Immunol 2003; 21: 377-423. (Pubitemid 37174536)
39. Gedey R, Jin XL, Hinthong O, Shisler JL. Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 2006; 80: 8676-8685. (Pubitemid 44384877)
40. Starace D, Riccioli A, D'Alessio A, Giampietri C, Petrungaro S, Galli R et al. Characterization of signaling pathways leading to Fas expression induced by TNF-alpha: pivotal role of NF-kappaB. FASEB J 2005; 19: 473-475. (Pubitemid 40316554)
41. Dupont PJ, Warrens AN. Fas ligand exerts its proinflammatory effects via neutrophil recruitment but not activation. Immunology 2007; 120: 133-139. (Pubitemid 44950478)
42. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714-1717. (Pubitemid 28549288)
43. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007; 5: 991-999. (Pubitemid 350070755)
44. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004; 10: 8114-8119. (Pubitemid 39587553)
45. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36. (Pubitemid 28133076)
46. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-429. (Pubitemid 23335841)
47. Lombard C, McKallip RJ, Hylemon PB, Nagarkatti PS, Nagarkatti M. Fas ligand-dependent and-independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver. Clin Immunol 2003; 109: 144-153. (Pubitemid 37338621)
48. Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007; 13: 5463-5473. (Pubitemid 47510374)